Immuneering Corp(IMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IMRX Immuneering Corp

休市中 05-29 16:00:00 EDT

5.77

+0.71

+14.03%

盘后5.82

+0.05+0.87%

19:53 EDT

最高5.85	最低5.06	成交量294.77万
今开5.17	昨收5.06	日振幅15.51%
总市值3.73亿	流通市值3.14亿	总股本6,457万
成交额1,624万	换手率5.42%	流通股本5,441万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":5.77,"timestamp":1780084800000,"preClose":5.06,"halted":0,"volume":2947707,"hourTrading":{"tag":"盘后","latestPrice":5.82,"preClose":5.77,"latestTime":"19:53 EDT","volume":58167,"amount":337142.064,"timestamp":1780098831468,"change":0.05,"changeRate":0.008666,"amplitude":0.034662},"delay":0,"changeRate":0.14031620553359683,"floatShares":54411779,"shares":64569967,"eps":-1.06,"marketStatus":"休市中","change":0.71,"latestTime":"05-29 16:00:00 EDT","open":5.17,"high":5.845,"low":5.06,"amount":16241489.4425868,"amplitude":0.155138,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.06,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":5.06,"preHourTrading":{"tag":"盘前","latestPrice":5.18,"preClose":5.06,"latestTime":"09:29 EDT","volume":57734,"amount":304408.6001636,"timestamp":1780061375046,"change":0.12,"changeRate":0.023715,"amplitude":0.102767},"postHourTrading":{"tag":"盘后","latestPrice":5.82,"preClose":5.77,"latestTime":"19:53 EDT","volume":58167,"amount":337142.064,"timestamp":1780098831468,"change":0.05,"changeRate":0.008666,"amplitude":0.034662},"volumeRatio":0.8196759466449784,"impliedVol":1.3253,"impliedVolPercentile":0.5333},"requestUrl":"/m/hq/s/IMRX","defaultTab":"news","newsList":[{"id":"1105605596","title":"Immuneering Corp仅报告贫血(16%)和中性粒细胞减少(18%)为发生率≥10%的3级及以上不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1105605596","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105605596?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:07","pubTimestamp":1779397636,"startTime":"0","endTime":"0","summary":"在Immuneering Corp的临床试验数据中，仅有贫血和中性粒细胞减少两种不良事件的发生率达到或超过了10%的门槛，且严重程度均为3级及以上。具体而言，贫血的发生率为16%，而中性粒细胞减少的发生率略高，为18%。这两项数据凸显了该治疗方案在患者耐受性方面的关键特征，为评估其安全性提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4563","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139557945","title":"Immuneering公布Atebimetinib联合化疗一线治疗转移性胰腺癌患者的中位总生存期达17.3个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1139557945","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139557945?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:01","pubTimestamp":1779397274,"startTime":"0","endTime":"0","summary":"Immuneering公司近日公布了一项临床数据，显示在接受Atebimetinib联合化疗作为一线治疗的转移性胰腺癌患者中，中位总生存期达到了17.3个月。这一结果对于晚期胰腺癌的治疗领域具有重要意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","IMRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167323867","title":"Immuneering公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1167323867","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167323867?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:46","pubTimestamp":1772801182,"startTime":"0","endTime":"0","summary":"Immuneering Corp（纳斯达克代码：IMRX）今日正式披露了公司2025财年第四季度及全年的财务数据，同时就当前业务发展状况向市场作出通报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","IMRX","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603124529","title":"Immuneering Corporation盘中异动 股价大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603124529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603124529?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:30","pubTimestamp":1768228240,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时30分，Immuneering Corporation股票出现异动，股价大幅下跌5.26%。截至发稿，该股报4.41美元/股，成交量4.7832万股，换手率0.07%，振幅0.00%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.00%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223040a4bb0dd6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223040a4bb0dd6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4563","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601333347","title":"优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601333347","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601333347?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:01","pubTimestamp":1767834062,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物技术公司Immuneering Corp.在周三盘后交易中暴跌约21%，此前其公布了atebimetinib作为胰腺癌一线疗法的2a期临床试验结果。该公司报告称，接受atebimetinib联合改良版吉西他滨/白蛋白结合型紫杉醇治疗的患者，12个月总生存率为64%。Immuneering特别指出，在超过10%的患者中仅观察到两种3级不良事件，即中性粒细胞减少症和贫血。其中，avutometinib联合疗法此前报告的总缓解率达83%，daraxonarasib则为55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4563","BK4139","BK4539","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180103519","title":"Immuneering公布一线胰腺癌患者接受Atebimetinib联合Mgnp治疗的12个月总生存率高达64%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180103519","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180103519?lang=zh_cn&edition=full","pubTime":"2026-01-08 05:01","pubTimestamp":1767819675,"startTime":"0","endTime":"0","summary":"生物科技公司Immuneering Corp (IMRX) 发布了令人瞩目的临床数据，显示其研发的Atebimetinib与Mgnp联合疗法在一线胰腺癌患者群体中取得突破性进展。治疗组患者在12个月时间点的总生存率达到了惊人的64%，这一数据显著超越了现有标准疗法的预期效果。\n胰腺癌作为恶性程度极高的肿瘤类型，长期面临治疗选择有限、患者预后差的挑战。此次公布的生存率数据为这一疾病领域的治疗带来了新的希望，也凸显了Atebimetinib联合疗法的潜在临床价值。该结果可能为后续的注册临床试验奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4539","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123783511","title":"Immuneering将在2026年1月7日公布一线胰腺癌患者接受Atebimetinib + Mgnp治疗的2a期临床试验12个月整体生存数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1123783511","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123783511?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:02","pubTimestamp":1766494972,"startTime":"0","endTime":"0","summary":"Immuneering将在2026年1月7日公布一线胰腺癌患者接受Atebimetinib + Mgnp治疗的2a期临床试验12个月整体生存数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4563","IMRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137012656","title":"Immuneering公司推进III期Atebimetinib试验，目标为首例一线转移性胰腺癌患者给药，同时获得FDA和EMA的对齐","url":"https://stock-news.laohu8.com/highlight/detail?id=1137012656","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137012656?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:08","pubTimestamp":1766005735,"startTime":"0","endTime":"0","summary":"Immuneering公司推进III期Atebimetinib试验，目标为首例一线转移性胰腺癌患者给药，同时获得FDA和EMA的对齐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4563","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162312611","title":"Immuneering预计将在2026年中期开始全球III期注册试验Mapkeeper 301的首位患者的给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1162312611","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162312611?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:07","pubTimestamp":1766005646,"startTime":"0","endTime":"0","summary":"Immuneering预计将在2026年中期开始全球III期注册试验Mapkeeper 301的首位患者的给药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IMRX","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516037876","title":"Immuneering Corporation盘中异动 股价大跌5.07%报1.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516037876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516037876?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:28","pubTimestamp":1741102100,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时28分，Immuneering Corporation股票出现异动，股价大幅下挫5.07%。截至发稿，该股报1.41美元/股，成交量6.3296万股，换手率0.20%，振幅4.39%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.30%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232820989bbbcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232820989bbbcd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4563","IMRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516655184","title":"Immuneering Corporation盘中异动 临近午盘快速跳水5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516655184","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516655184?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:43","pubTimestamp":1741020186,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时43分，Immuneering Corporation股票出现波动，股价快速下挫5.45%。截至发稿，该股报1.56美元/股，成交量10.2418万股，换手率0.33%，振幅4.85%。Immuneering Corporation股票所在的生物技术行业中，整体跌幅为0.38%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040043069637cb7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040043069637cb7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4563","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514773042","title":"Immuneering Corporation盘中异动 早盘股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514773042","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514773042?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:01","pubTimestamp":1740412884,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日00时01分，Immuneering Corporation股票出现波动，股价大幅下跌5.11%。截至发稿，该股报1.67美元/股，成交量10.2635万股，换手率0.33%，振幅6.25%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.16%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225000124a25229d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225000124a25229d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4539","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513297302","title":"Immuneering Corporation盘中异动 早盘股价大涨5.26%报1.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513297302","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513297302?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:24","pubTimestamp":1740155086,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时24分，Immuneering Corporation股票出现异动，股价大幅上涨5.26%。截至发稿，该股报1.80美元/股，成交量13.5951万股，换手率0.44%，振幅5.32%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.33%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002446a24ec96e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002446a24ec96e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","IMRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509776772","title":"Immuneering Corporation盘中异动 大幅下挫5.03%报1.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509776772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509776772?lang=zh_cn&edition=full","pubTime":"2025-02-08 04:28","pubTimestamp":1738960085,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日04时28分，Immuneering Corporation股票出现波动，股价大幅下挫5.03%。截至发稿，该股报1.89美元/股，成交量34.7832万股，换手率1.12%，振幅6.03%。Immuneering Corporation股票所在的生物技术行业中，整体跌幅为0.79%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208042805abc67588&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208042805abc67588&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","IMRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509277493","title":"Immuneering Corporation盘中异动 早盘股价大涨5.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509277493","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509277493?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:03","pubTimestamp":1738854218,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日23时03分，Immuneering Corporation股票出现异动，股价快速拉升5.71%。Immuneering Corporation股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为5022.88%、1110.98%、126.42%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为90.69%、39.93%、36.09%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206230338a23bd5ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206230338a23bd5ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","IMRX","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507767765","title":"Immuneering Corporation盘中异动 下午盘股价大涨5.24%报2.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507767765","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507767765?lang=zh_cn&edition=full","pubTime":"2025-01-31 04:01","pubTimestamp":1738267273,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日04时01分，Immuneering Corporation股票出现异动，股价快速上涨5.24%。截至发稿，该股报2.01美元/股，成交量23.0271万股，换手率0.74%，振幅5.24%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Dominari Holdings Inc.涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1804.70%、327.29%、253.17%，振幅较大的相关个股有Dominari Holdings Inc.、Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为70.55%、65.98%、64.10%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131040113961461c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131040113961461c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","BK4539","BK4139","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506021343","title":"Immuneering Corporation盘中异动 快速跳水5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506021343","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506021343?lang=zh_cn&edition=full","pubTime":"2025-01-28 00:15","pubTimestamp":1737994504,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日00时15分，Immuneering Corporation股票出现异动，股价大幅跳水5.34%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.85%。其相关个股中，Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大，Onconetix, Inc.、Dogwood Therapeutics, Inc.、Evaxion Biotech As较为活跃，换手率分别为2014.85%、474.64%、220.37%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为86.84%、85.35%、65.16%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128001504abba7670&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128001504abba7670&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","IMRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506818581","title":"Immuneering Corporation盘中异动 下午盘急速下挫5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506818581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506818581?lang=zh_cn&edition=full","pubTime":"2025-01-25 04:28","pubTimestamp":1737750532,"startTime":"0","endTime":"0","summary":"北京时间2025年01月25日04时28分，Immuneering Corporation股票出现波动，股价大幅下挫5.12%。Immuneering Corporation股票所在的生物技术行业中，整体跌幅为0.70%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Dermata Therapeutics Inc C/Wts 、Evaxion Biotech As涨幅较大，Evaxion Biotech As、Pmgc Holdings Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为4646.03%、2424.04%、1770.35%，振幅较大的相关个股有Neuphoria Therapeutics Inc.、Celularity Inc C/Wts 16/07/2026 、Evaxion Biotech As，振幅分别为261.67%、251.21%、137.09%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125042852abb799a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125042852abb799a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","IMRX","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505201974","title":"Immuneering Corporation盘中异动 大幅上涨5.20%报2.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505201974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505201974?lang=zh_cn&edition=full","pubTime":"2025-01-22 01:19","pubTimestamp":1737479967,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日01时19分，Immuneering Corporation股票出现波动，股价大幅上涨5.20%。截至发稿，该股报2.13美元/股，成交量25.319万股，换手率0.82%，振幅5.45%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为1.88%。其相关个股中，Camp4 Therapeutics Corporation、Channel Therapeutics Corporation、Genelux Corporation涨幅较大，Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃，换手率分别为770.52%、503.85%、187.32%，振幅较大的相关个股有Channel Therapeutics Corporation、Klotho Neurosciences Inc C/Wts 21/06/2029 、Dogwood Therapeutics, Inc.，振幅分别为96.32%、41.33%、38.48%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122011927960bd6ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122011927960bd6ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4539","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504919636","title":"Immuneering Corporation盘中异动 临近午盘股价大涨5.58%报2.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504919636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504919636?lang=zh_cn&edition=full","pubTime":"2025-01-18 00:32","pubTimestamp":1737131541,"startTime":"0","endTime":"0","summary":"北京时间2025年01月18日00时32分，Immuneering Corporation股票出现波动，股价快速拉升5.58%。截至发稿，该股报2.07美元/股，成交量33.3435万股，换手率1.07%，振幅4.89%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.59%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118003221abaecc78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118003221abaecc78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","BK4539","BK4139","IMRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":0.0705},{"period":"1month","weight":0.099},{"period":"3month","weight":0.1563},{"period":"6month","weight":-0.2467},{"period":"1year","weight":2.4041},{"period":"ytd","weight":-0.1231}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immuneering Corporation于2008年在特拉华州注册成立。该公司是一家临床阶段的肿瘤学公司，寻求为广泛的癌症患者群体开发和商业化通用RAS/RAF药物。该公司的目标是通过对MAPK通路的深度循环抑制来实现这种普遍的RAS/RAF活性，在保留健康细胞的同时冲击癌细胞。公司的包容性方法将公司与狭义靶向精准疗法区分开来，后者仅限于携带特定突变的肿瘤患者。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.22671},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02029},{"month":3,"riseRate":0.4,"avgChangeRate":0.059054},{"month":4,"riseRate":0.2,"avgChangeRate":-0.166499},{"month":5,"riseRate":0.4,"avgChangeRate":0.024846},{"month":6,"riseRate":0.75,"avgChangeRate":0.3519},{"month":7,"riseRate":0.75,"avgChangeRate":0.027683},{"month":8,"riseRate":0.4,"avgChangeRate":0.157517},{"month":9,"riseRate":0.8,"avgChangeRate":0.592866},{"month":10,"riseRate":0.2,"avgChangeRate":-0.073665},{"month":11,"riseRate":0.4,"avgChangeRate":-0.104912},{"month":12,"riseRate":0.4,"avgChangeRate":-0.101218}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immuneering Corp(IMRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immuneering Corp(IMRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}